Clinical Trial Update: GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating growth hormone, IGF-I, and somatostatin analogues in advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IGF-1 (insulin-like growth factor 1)
• Lanreotide (lanreotide)
• OCTREOTIDE (OCTREOTIDE ACETATE)
• Somatropin (somatropin)

Snippet

Sponsor: Federico II University | Conditions: Advanced Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: COMPLETED